Ocrevus (ocrelizumab) effectively manages relapsing and primary progressive multiple sclerosis by depleting CD20-positive B cells. Key benefits include a 46% reduction in annual relapses and 25% slower disability progression. Potential risks involve infusion reactions, increased respiratory infection susceptibility, and rare cases of PML or liver injury.
- Disease control: Reduces new brain lesions by 77–83% compared to standard interferon beta-1a treatments.
- Mobility preservation: Delays wheelchair dependence by approximately 7 years in early primary progressive MS cases.
- Infusion reactions: Affects 34–40% of patients, typically causing itching, rash, fever, or nausea.
- Infection risk: Increases vulnerability to shingles, hepatitis B reactivation, and frequent respiratory infections.
Bookimed Expert Insight: While Ocrevus costs between $10,000 and $15,000 in Turkey, patients often overlook the significant savings compared to the $80,000 US average. Leading centers like Anadolu Medical Center or Medipol Mega utilize JCI-accredited protocols to manage the common 40% infusion reaction rate safely. Many patients successfully switch to this biannual dosing after failing daily medications, reporting near-zero relapses in the first 2 years.
Patient Consensus: Patients value the freedom of twice-yearly infusions over daily or weekly injections, often describing the results as life-changing for energy levels. Despite benefits, many emphasize the need for strict infection monitoring and suggest completing all necessary vaccinations before starting therapy.
